View this email as a webpage

Rutgers Cancer Institute of New Jersey



Clinical Trials Connection

A Cancer Resource for Healthcare Professionals October 2013

Resources for Physicians

Send to a Colleague

Join Our Mailing List

Antoinette R. Tan, MD, MHSc is the director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey and a medical oncologist specializing in the evaluation and treatment of breast cancer at the institute's Stacy Goldstein Breast Cancer Center.

Contact Dr. Tan:
tanan@cinj.rutgers.edu
732-235-9867

Clinical Trial Spotlight

Phase IA/1B Study of CC-122 for Subjects with Advanced Solid Tumors, NHL and Multiple Myeloma

The purpose of this clinical trial is to determine the safety and tolerability of CC-122 given orally and to define the non-tolerable dose, MDT and the recommended

Phase I Clinical Trials

View all related clinical trials View printable version

M13-695: A Phase I Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects with Solid Tumors

The study aims to:

- Assess and compare the bioavailability of three test extended release (ER) formulations of veliparib with that of the current imemdiate release formulation of veliparib.
- Evaluate the potential effect of food on the oral bioavailability of three test extended release (ER) formulations of veliparib.
- Establish the maximum tolerated dose (MTD) and to establish the recommended Phase II dose (RPTD) and schedule for one or more of the ER formulations.

Learn more about this trial

A Phase I Study of Pazopanib in Combination with Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients with Advanced Solid Tumors

The study aims to:

- Determine the safety and tolerability of pazopanib in combination with weekly paclitaxel and weekly carboplatin on Days 1, 8, and 15 every 28 days in patients with advanced solid tumors.
- Determine the maximum tolerated dose (MTD) of pazopanib in combination with weekly paclitaxel and weekly carboplatin on Days 1, 8, and 15 every 28 days in patients with advanced solid tumors.
- Determine the effect of pazopanib on the pharmacokinetics of paclitaxel and carboplatin.

Learn more about this trial

Phase II dose. The study also aims to determine the PK and extent of urinary excretion of CC-122.

Learn more about this clinical trial

Other Available Trials

Breast

Gastrointestinal

Gynecologic

Hematologic

Melanoma

Prostate

Thoracic

NCI CCC

A Comprehensive Cancer Center Designated by the National Cancer Institute

TED12471: A Phase I Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients with Solid Tumors or Lymphoma

The study aims to:

- Evaluate the safety and tolerability of SAR245409 administered as a tablet formulation on 2 treatment schedules (once daily [QD] and twice daily [BID] dosing) in patients with solid tumors or lymphoma.
- Evaluate the plasma pharmacokinetics (PK) of oral administration of SAR245409 given as a tablet formulation on QD and BID treatment schedules in patients with solid tumors or lymphoma.
- Obtain preliminary information on the effect of food on the plasma PK of oral administration of SAR245409 as a tablet formulation in patients with solid tumors or lymphoma.

Learn more about this trial

A Study to Determine Whether Necitumumab (IMC-11F8) Monotherapy Affects the Corrected QT (QTc) Interval in Patients With Advanced Solid Tumors

The study aims to:

- Determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among patients with advanced solid tumors refractory to standard treatment or for which no standard treatment is available.
- Determine whether treatment with necitumumab affects other electrocardiographic parameters in this study population.
- Assess the safety, tolerability, and immunogenicity of necitumumab monotherapy.

Learn more about this trial

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients. Learn more